News
Quantum Genomics publie ses résultats financiers semestriels et fait le point sur l'activité des 9 premiers mois de l'année
Paris, le 3 octobre 2017
Résultats positifs de l'étude de phase IIa avec QGC001 dans l'hypertension artérielle
Lancement de NEW-HOPE, essai clinique ciblé de phase II aux....
Fighting Debt Demons, Valeant Pharmaceuticals Just Priced a New Debt Offering
The theme of 2017 for embattled drug developer Valeant Pharmaceuticals (NYSE: VRX) is "baby steps." After a miserable 2015 and 2016, which saw the company get buried under debt and accused of....
Intercept Pharmaceuticals, Inc. Was Halved in September, but Presents an Intriguing Opportunity
Shares of Intercept Pharmaceuticals (NASDAQ: ICPT), a small-cap biotech company with a focus on discovering medicines to treat non-viral, progressive liver diseases, lost roughly half of its value....
2 Clear-Cut Reasons Teva Pharmaceutical Industries Tacked on $1.3 Billion in Market Cap in September
Shares of Teva Pharmaceutical Industries (NYSE: TEVA), an Israeli-based developer of branded and generic drugs, gained more than 8% during September, totaling $1.3 billion in market cap, according....
Why bluebird bio, Inc. Stock Gained 10% in September
Shares of bluebird bio, Inc. (NASDAQ: BLUE), a clinical-stage biotech developing cell-based therapies, rose 10% in September according to data from S&P Global Market Intelligence. Although....
Is This How Drugmakers Will Kill Biosimilars?
Pfizer (NYSE: PFE) has filed a lawsuit accusing Johnson & Johnson (NYSE: JNJ) of strong-arming insurers into excluding its Remicade biosimilar, Inflectra, from their reimbursement lists. If....
After Intepirdine Flunked in Alzheimer’s Disease, Is Axovant Sciences a Buy?
Hope was running high at Axovant Sciences (NASDAQ: AXON) that that teaming up their drug intepirdine with the top-selling Alzheimer's disease treatment, Aricept, could improve patients' lives.....
Good News and Bad News for Gilead Sciences: Which Carries More Weight?
You knew it wouldn't take too long for euphoria over Gilead Sciences' (NASDAQ: GILD) planned acquisition of Kite Pharma to wear off. The question was whether the next round of news for the big....
Why AcelRx Pharmaceuticals Inc Jumped Higher Today
AcelRx Pharmaceuticals (NASDAQ: ACRX) closed up nearly 20% on Monday, having jumped a whopping 64% over the last week. While there's no apparent news today to drive the stock higher -- or within....
Why MannKind Corporation Popped Today
Shares of MannKind Corporation (NASDAQ: MNKD), a commercial-stage biopharma focused on inhaled insulin, rose as much as 13% in afternoon trading on Monday. Shareholders can largely thank two....
Sarepta Therapeutics Stock Soars Despite Adverse Event Worries
Late last week, some Sarepta Therapeutics (NASDAQ: SRPT) investors were worried. Now the weekend is over, and all of those worries seem to have dissipated.Concerns arose after the U.S. Food and....
3 Beaten-Down Biotech Stocks to Buy Right Now
Biotech stocks that crater on negative clinical results or unfavorable regulatory developments can sometimes represent outstanding investing opportunities. Not all beaten-down biotech stocks,....
Here's Why Rigel Pharmaceuticals, Inc. Is Jumping Higher Today
Shares of Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL), a clinical-stage biotech, are on the rise today after the company announced results of a recent meeting with the Food and Drug Administration.....
Why Seres Therapeutics Inc. Stock Is Tanking Today
Shares of Seres Therapeutics (NASDAQ: MCRB), a clinical-stage biotech focused on microbiome therapeutics, were down 19% as of 11:25 a.m. EDT on Monday. The decline can be traced to the release of....
AbbVie Stock Upgraded: What You Need to Know
Every day, Wall Street analysts upgrade some stocks, downgrade others, and "initiate coverage" on a few more. But do these analysts even know what they're talking about? Today, we're taking one....
6 Reasons I've Been Aggressively Buying Teva Pharmaceutical Industries
Israeli-based Teva Pharmaceutical Industries (NYSE: TEVA) has had quite a run of bad luck. Like really, really bad luck. Its share price has been cut by roughly three quarters in less than two....
Why Dynavax Technologies Corporation Stock Is Rising Today
Shares of Dynavax Technologies Corporation (NASDAQ: DVAX) are up by over 11% in pre-market trading on modest volume this morning, following a report that management is exploring different....
Better Buy: Gilead Sciences, Inc. vs. Pfizer
The biopharmaceutical industry has been exceptionally kind to investors over the past six years because of the introduction of several new classes of drugs, greater insurance coverage for....
Best Buy: Johnson & Johnson, Pfizer, or Gilead Sciences?
Remember the old game show "Let's Make a Deal"? It was originally hosted by the recently deceased Monty Hall, and its current iteration is hosted by comedian Wayne Brady. Contestants can choose....
This U.S. Marijuana Stock Is Arguably the Best on the Market -- and It's Dirt Cheap
What's the best U.S. marijuana stock on the market right now?Including only the U.S. in the question excludes several of the top candidates, such as U.K.-based GW Pharmaceuticals (NASDAQ: GWPH)....
Pfizer Exposes the Sordid Underbelly of Drug Prices
Johnson & Johnson's (NYSE: JNJ) one of the largest drugmakers in the world, and according to a lawsuit Pfizer (NYSE: PFE) has filed, it's leveraging its size to negotiate contracts that....
Better Buy: Exelixis, Inc. vs. Immunogen, Inc.
It's been a really good year for Exelixis (NASDAQ: EXEL). The biotech's share price has jumped more than 60% so far in 2017, thanks to continued momentum for its kidney cancer drug Cabometyx. But....
3 Biotech Stocks That Soared This Week: Are They Buys?
There's nothing like good results from a clinical study to light a fire beneath a biotech stock. That's what has happened with several biotechs over the last few days.Madrigal Pharmaceuticals....
The Unusual Reason PTC Therapeutics, Inc. Is Bouncing Back Today
Despite a 10-1 advisory committee vote against PTC Therapeutics, Inc.'s (NASDAQ: PTCT) experimental Duchenne muscular dystrophy (DMD) drug Thursday, the stock is on the rise on Friday. A slight....
1 Great Biotech Stock You Have Never Heard Of
About 90% of drug candidates that enter clinical trials never make it to market. That brutal fact makes the small-cap biotech sector a tough place for investors to put their money to work.However,....